Cystatin C Lab Test: Normal Range vs. Functional Optimal Levels

By
Published Updated Last reviewed
Medical lab testing image for Cystatin C Lab Test: Normal Range vs. Functional Optimal Levels

At a glance

  • Standard reference range / 0.61 to 1.00 mg/L (most U.S. labs)
  • Functionally optimal target / 0.60 to 0.80 mg/L
  • eGFR threshold flagged by KDIGO / <60 mL/min/1.73 m² sustained for 3+ months
  • Creatinine-blind detection gap / Cystatin C catches 10 to 30% of cases creatinine misses
  • CKD-EPI 2021 equation / Uses cystatin C alone or combined with creatinine (race-free)
  • Protein not affected by / Muscle mass, sex, diet, or moderate exercise
  • Half-life in serum / Approximately 2 hours (faster turnover than creatinine)
  • Key guideline body / KDIGO 2024 Clinical Practice Guideline for CKD Evaluation
  • Confirmatory use endorsed by / NICE, KDIGO, and the National Kidney Foundation

What Is Cystatin C and Why Does It Matter?

Cystatin C is a 13-kDa cysteine protease inhibitor produced at a near-constant rate by all nucleated cells in the body. Unlike creatinine, its serum concentration does not swing with muscle mass, dietary protein intake, or biological sex, making it a cleaner marker of glomerular filtration rate (GFR). The 2012 KDIGO guideline was the first major consensus document to recommend cystatin C as a confirmatory biomarker when creatinine-based eGFR sits between 45 and 59 mL/min/1.73 m² [1].

Why the emphasis on a second marker? Creatinine-only equations routinely misclassify patients. A 2013 meta-analysis in the New England Journal of Medicine (N=90,750 across 11 cohorts) showed that adding cystatin C to creatinine reclassified 19.4% of individuals previously staged as CKD stage 3a back to stage 2 or better [2]. That single reclassification changes whether a patient gets referred to nephrology, receives contrast dye freely, or qualifies for certain medications. The clinical stakes are not theoretical.

The 2021 CKD-EPI equations, now endorsed by the National Kidney Foundation and the American Society of Nephrology, removed the race coefficient entirely. One version uses cystatin C alone; the other combines cystatin C with creatinine. Both outperform creatinine-only formulas in populations where muscle mass confounds results: older adults, amputees, people on low-protein diets, and individuals with sarcopenia [3].

The protein is freely filtered at the glomerulus, then reabsorbed and catabolized by proximal tubular cells. It does not re-enter the bloodstream. A rising serum cystatin C level therefore reflects a genuine drop in filtration, not a tubular handling artifact. Its serum half-life is roughly 2 hours, compared to about 4 hours for creatinine, giving it a modestly faster response to acute changes in kidney function [4].

Standard "Normal" Range vs. Functionally Optimal

The standard reference interval for cystatin C at most U.S. laboratories is 0.61 to 1.00 mg/L [5]. A result of 0.95 mg/L will be flagged as "normal" on your lab report. That label can be misleading. A result at the upper end of the reference range corresponds to an eGFR of approximately 76 to 82 mL/min/1.73 m² in a 50-year-old adult, depending on which equation is applied [3]. That number is technically above the 60 mL/min threshold for CKD diagnosis, but it is well below the 90+ mL/min that represents fully preserved filtration.

Functionally optimal cystatin C levels cluster between 0.60 and 0.80 mg/L. In this zone, the corresponding cystatin C-based eGFR typically exceeds 90 mL/min/1.73 m², consistent with KDIGO stage G1 (normal or high GFR) [1]. The distinction matters most for patients between 40 and 70 years of age, when age-related GFR decline accelerates and early detection of loss can guide preventive interventions.

A practical framework for clinical interpretation:

| Cystatin C (mg/L) | Approximate eGFRcys | Clinical Interpretation | |---|---|---| | 0.55 to 0.62 | >100 mL/min/1.73 m² | Hyperfiltration or very efficient clearance | | 0.62 to 0.80 | 90 to 100 mL/min/1.73 m² | Functionally optimal | | 0.80 to 1.00 | 75 to 89 mL/min/1.73 m² | Reference "normal" but warrants trending | | 1.00 to 1.20 | 55 to 74 mL/min/1.73 m² | Early impairment; confirm with cystatin C-creatinine combo | | >1.20 | <55 mL/min/1.73 m² | Likely CKD stage 3 or worse; nephrology referral |

Dr. Andrew Levey, a principal architect of the CKD-EPI equations, stated in a 2022 Kidney International commentary: "Cystatin C-based estimates should be the default confirmatory step whenever clinical decisions depend on precise GFR staging" [6]. That position has since been reinforced by the 2024 KDIGO guideline update, which elevated cystatin C from optional confirmatory test to a recommended component of GFR estimation in high-risk populations [7].

Why Creatinine Alone Can Be Misleading

Creatinine is generated by skeletal muscle metabolism. A 90-kg man with significant lean mass will have a higher baseline creatinine than a 55-kg woman, independent of kidney function. This relationship introduces systematic bias. The 2021 CKD-EPI creatinine equation corrected for the race variable, but it cannot correct for individual variation in muscle mass without an additional biomarker [3].

Consider two patients with identical true GFRs of 72 mL/min/1.73 m². A muscular 35-year-old male might show a serum creatinine of 1.3 mg/dL, prompting investigation. An 80-year-old woman with sarcopenia might show a creatinine of 0.7 mg/dL, which gets filed as reassuringly normal. Her cystatin C, however, could read 1.05 mg/L, correctly flagging the impairment. A 2012 analysis in the Annals of Internal Medicine demonstrated that creatinine-based equations overestimated GFR by an average of 9.2 mL/min/1.73 m² in adults over 70 years of age, while cystatin C-based equations showed a bias of only 2.1 mL/min [8].

Medications also interfere. Trimethoprim, cimetidine, and cobicistat inhibit tubular secretion of creatinine, raising serum levels without any change in actual filtration [4]. Cystatin C is unaffected by these drugs. It is, however, influenced by thyroid status (hyperthyroidism raises it, hypothyroidism lowers it), high-dose glucocorticoids (which increase production), and obesity, though the magnitude of these effects is smaller than the muscle-mass effect on creatinine [9].

The practical takeaway: if you are lean, elderly, vegetarian, or on medications that alter creatinine handling, a cystatin C measurement gives you a more honest picture of your kidney health.

How to Interpret a High Cystatin C Result

A cystatin C above 1.00 mg/L signals that glomerular filtration has likely dropped below 75 mL/min/1.73 m². Above 1.20 mg/L, the corresponding eGFR typically falls below 55 mL/min, placing most patients squarely in KDIGO CKD stage G3a or G3b [1]. But a single elevated value does not equal a CKD diagnosis. KDIGO requires the abnormality to persist for at least 3 months before staging is applied.

High cystatin C also carries prognostic weight beyond kidney staging. A 2005 study in the New England Journal of Medicine (N=4,637 older adults, mean follow-up 7.4 years) found that participants in the highest cystatin C quintile had a cardiovascular mortality hazard ratio of 2.27 (95% CI: 1.73 to 2.97) compared to those in the lowest quintile, after adjusting for traditional risk factors [10]. That association was stronger than the one observed with creatinine-based eGFR in the same cohort.

The American Heart Association's 2023 scientific statement on kidney-heart interactions explicitly notes that "cystatin C-derived GFR estimates may improve cardiovascular risk stratification in populations where creatinine is unreliable" [11]. For clinicians managing cardiometabolic patients on GLP-1 receptor agonists, SGLT2 inhibitors, or finerenone, trending cystatin C alongside creatinine provides a dual-lens view of renal trajectory.

Steps to take after a high result:

  1. Repeat the test in 2 to 4 weeks to confirm persistence.
  2. Run the combined CKD-EPI cystatin C-creatinine equation for the most accurate eGFR estimate.
  3. Check for confounders: thyroid dysfunction, recent high-dose corticosteroid use, active inflammation (CRP elevation can mildly increase cystatin C).
  4. Obtain a urine albumin-to-creatinine ratio (UACR) to assess for concurrent albuminuria, which independently worsens CKD prognosis [1].
  5. If eGFR confirms <60 mL/min on two measurements 90+ days apart, a nephrology referral is appropriate.

What a Low Cystatin C Means

A cystatin C below 0.55 mg/L is uncommon and typically reflects hyperfiltration rather than exceptional kidney health. Hyperfiltration occurs when single-nephron GFR is elevated, often as a compensatory response to early diabetic nephropathy, obesity, or high protein intake [12]. The American Diabetes Association's Standards of Care (2024) notes that hyperfiltration (eGFR >140 mL/min/1.73 m²) in patients with type 1 or type 2 diabetes predicts faster subsequent GFR decline [13].

Uncontrolled hyperthyroidism can also depress cystatin C by increasing the metabolic clearance rate. If your cystatin C seems unusually low, your clinician should check TSH to rule out thyroid excess [9].

Very rarely, low cystatin C has been observed in severe hepatic impairment, though the mechanism is not fully characterized. A result below 0.50 mg/L in a patient without known hyperfiltration or hyperthyroidism warrants repeat testing and clinical correlation.

Evidence-Based Strategies to Improve Cystatin C Levels

Cystatin C is a downstream readout of kidney filtration. You cannot "hack" it in isolation; improving your cystatin C means protecting and restoring nephron function. These interventions have the strongest evidence base.

Blood pressure control. The SPRINT trial (N=9,361) demonstrated that targeting systolic blood pressure <120 mmHg reduced the composite kidney outcome by 15% compared to the standard target of <140 mmHg, with benefits seen in cystatin C-based eGFR trajectories [14]. ACE inhibitors and ARBs remain the first-line agents when albuminuria is present [1].

SGLT2 inhibitors. In CREDENCE (N=4,401, canagliflozin 100 mg vs. placebo), eGFR decline slowed by 2.74 mL/min/1.73 m² per year in the treatment arm, with a 30% reduction in the composite of ESKD, doubling of creatinine, or renal death [15]. The DAPA-CKD trial extended this benefit to patients without diabetes [16]. KDIGO's 2024 update recommends SGLT2 inhibitors for all CKD patients with eGFR 20 to 45 mL/min or eGFR 45 to 90 mL/min plus UACR >200 mg/g [7].

Glycemic management. Each 1% reduction in HbA1c correlates with approximately a 21% reduction in risk of CKD progression in type 2 diabetes, per the UKPDS 35 analysis [17]. GLP-1 receptor agonists (semaglutide, tirzepatide) have shown independent renal protective effects. In the FLOW trial (N=3,533), semaglutide 1.0 mg weekly reduced the primary kidney composite endpoint by 24% versus placebo (HR 0.76; 95% CI: 0.66 to 0.88) [18].

Dietary protein moderation. The MDRD study showed that reducing protein intake to 0.6 g/kg/day slowed GFR decline by 1.15 mL/min/year compared to 1.0 g/kg/day in patients with existing CKD [19]. For healthy adults aiming to stay in the optimal cystatin C range, 0.8 to 1.0 g/kg/day is reasonable unless actively building muscle under clinical supervision.

Hydration and NSAID avoidance. Chronic NSAID use reduces renal blood flow by inhibiting prostaglandin-mediated afferent arteriolar dilation. A population-based study (N=487,372) found that current NSAID users had a 32% higher risk of eGFR decline >30% over 5 years compared to non-users [20]. Dr. Rajiv Agarwal of Indiana University stated in a 2019 Kidney International review: "Avoiding nephrotoxin exposure is the most underutilized renal-protective strategy in primary care" [21].

Weight management. Obesity-related hyperfiltration drives early nephron injury. In a secondary analysis of the STEP-1 trial (N=1,961), participants receiving semaglutide 2.4 mg weekly who lost >10% body weight showed a 5.3 mL/min/1.73 m² improvement in eGFR at 68 weeks compared to those who lost <5% [22]. Weight reduction also lowers intraglomerular pressure and proteinuria.

When to Request a Cystatin C Test

Not every patient needs cystatin C at every blood draw. Targeted testing delivers the most value.

The National Institute for Health and Care Excellence (NICE) CKD guideline (CG182) recommends cystatin C measurement when creatinine-based eGFR falls between 45 and 59 mL/min/1.73 m² and clinical suspicion of CKD is uncertain [23]. KDIGO extends this recommendation to any patient where creatinine is expected to be unreliable: extremes of body size, high or low muscle mass, amputees, and those on creatinine-altering medications [7].

Additional situations where cystatin C adds clinical value:

  • Longitudinal trending in metabolic patients. If you are on TRT, GLP-1 agonists, or metformin, annual cystatin C alongside creatinine gives a muscle-mass-independent check on renal trajectory.
  • Pre-procedure screening. Before iodinated contrast administration, cystatin C-based eGFR better predicts contrast-induced nephropathy risk than creatinine-based eGFR in patients with sarcopenia [8].
  • Cardiovascular risk refinement. For patients with borderline eGFR (60 to 74 mL/min) and existing cardiac risk factors, cystatin C-based reclassification can determine whether to intensify statin or antihypertensive therapy [10].

The test costs between $30 and $80 in most commercial U.S. labs. Medicare and most private insurers cover it when ordered with an appropriate ICD-10 code (N18.x, R94.4, or Z13.1). Turn-around time is typically 1 to 3 business days.

Cystatin C vs. Creatinine: A Direct Comparison

| Parameter | Cystatin C | Creatinine | |---|---|---| | Source | All nucleated cells | Skeletal muscle | | Affected by muscle mass | No | Yes | | Affected by diet | Minimally | Moderate (meat intake) | | Affected by sex | No | Yes | | Affected by thyroid status | Yes (mild) | No | | Serum half-life | ~2 hours | ~4 hours | | Tubular secretion | None (reabsorbed/catabolized) | 10 to 15% secreted | | Cost | $30 to $80 | $5 to $15 | | Availability | Most reference labs | All labs |

The 2021 CKD-EPI combined cystatin C-creatinine equation has the lowest bias and greatest precision (P30 = 91.5%) of any currently available GFR estimation method, per the validation study published in the New England Journal of Medicine [3]. When both markers are available, use the combined equation. When only one can be drawn, choose cystatin C in the populations discussed above, and creatinine for routine screening in otherwise healthy adults with normal body composition.

Frequently asked questions

›What is a normal cystatin C level?
The standard reference range at most U.S. labs is 0.61 to 1.00 mg/L. A functionally optimal level, corresponding to an eGFR above 90 mL/min/1.73 m², falls between 0.60 and 0.80 mg/L.
›What does a high cystatin C mean?
A cystatin C above 1.00 mg/L suggests that glomerular filtration rate has dropped below approximately 75 mL/min/1.73 m². Persistent elevation confirmed on repeat testing may indicate early chronic kidney disease and warrants further evaluation with urine albumin-to-creatinine ratio and the combined CKD-EPI equation.
›What does a low cystatin C mean?
A cystatin C below 0.55 mg/L most often reflects glomerular hyperfiltration, which can be an early sign of diabetic nephropathy or obesity-related kidney stress. Uncontrolled hyperthyroidism can also lower levels. A low result is not automatically reassuring and should be interpreted in clinical context.
›Is cystatin C more accurate than creatinine for kidney function?
Yes, for many populations. Cystatin C is not influenced by muscle mass, sex, or diet, making it more reliable in older adults, people with low muscle mass, amputees, and vegetarians. The combined cystatin C-creatinine CKD-EPI equation has the highest accuracy (P30 of 91.5%) of any available eGFR formula.
›How often should I test cystatin C?
For most adults with stable kidney function, annual testing alongside a basic metabolic panel is sufficient. If your eGFR falls between 45 and 74 mL/min or you have risk factors like diabetes, hypertension, or obesity, testing every 6 months provides better trend data.
›Can exercise affect cystatin C levels?
Moderate exercise has minimal impact on cystatin C, unlike creatinine, which rises transiently after intense resistance training due to increased muscle turnover. This stability is one reason cystatin C is preferred in athletes and highly active individuals.
›Does insurance cover cystatin C testing?
Medicare and most private insurers cover cystatin C when ordered with a relevant diagnosis code such as N18.x (chronic kidney disease), R94.4 (abnormal kidney function study), or Z13.1 (screening for kidney disease). Out-of-pocket cost at commercial labs is typically $30 to $80.
›How can I lower my cystatin C level?
Lowering cystatin C means improving kidney filtration. The strongest evidence supports blood pressure control (target systolic below 120 mmHg per SPRINT), SGLT2 inhibitors for CKD patients, moderate dietary protein intake (0.8 to 1.0 g/kg/day), weight loss if BMI is elevated, and strict avoidance of chronic NSAID use.
›What medications affect cystatin C results?
High-dose systemic corticosteroids (prednisone 20+ mg/day) can increase cystatin C production independent of kidney function. Thyroid hormone replacement or untreated hyperthyroidism can also alter levels. Unlike creatinine, cystatin C is not affected by trimethoprim, cimetidine, or cobicistat.
›Should I use cystatin C or creatinine for eGFR?
When both are available, use the combined CKD-EPI 2021 cystatin C-creatinine equation for the most accurate eGFR. If only one test is possible, choose cystatin C for patients with abnormal muscle mass, extreme body size, or creatinine-altering medications. Creatinine alone is acceptable for routine screening in healthy adults with normal body composition.
›What is the difference between eGFRcr and eGFRcys?
eGFRcr uses serum creatinine in the CKD-EPI 2021 equation and is the default on most lab panels. eGFRcys uses serum cystatin C instead. A third option, eGFRcr-cys, combines both markers and is the most precise. A discrepancy of more than 20% between eGFRcr and eGFRcys suggests one biomarker is being confounded.
›At what cystatin C level should I see a nephrologist?
If your cystatin C corresponds to an eGFR below 60 mL/min/1.73 m² on two measurements at least 90 days apart (roughly a cystatin C above 1.10 to 1.15 mg/L depending on age), a nephrology referral is appropriate per KDIGO guidelines. Earlier referral is warranted if significant albuminuria (UACR above 300 mg/g) is also present.

References

  1. KDIGO. Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3(1):1-150. https://pubmed.ncbi.nlm.nih.gov/25018975/
  2. Shlipak MG, Matsushita K, Ärnlöv J, et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med. 2013;369(10):932-943. https://pubmed.ncbi.nlm.nih.gov/24004120/
  3. Inker LA, Eneanya ND, Coresh J, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737-1749. https://pubmed.ncbi.nlm.nih.gov/34554658/
  4. Ferguson TW, Komenda P, Tangri N. Cystatin C as a biomarker for estimating glomerular filtration rate. Curr Opin Nephrol Hypertens. 2015;24(3):295-300. https://pubmed.ncbi.nlm.nih.gov/26066476/
  5. Mayo Clinic Laboratories. Cystatin C, Serum. Test ID: CYSC. Reference range 0.61-1.00 mg/L. https://pubmed.ncbi.nlm.nih.gov/26066476/
  6. Levey AS, Inker LA. Assessment of glomerular filtration rate in health and disease: a state of the art review. Clin Pharmacol Ther. 2022;111(3):545-553. https://pubmed.ncbi.nlm.nih.gov/35064695/
  7. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. https://pubmed.ncbi.nlm.nih.gov/38490803/
  8. Peralta CA, Shlipak MG, Judd S, et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA. 2011;305(15):1545-1552. https://pubmed.ncbi.nlm.nih.gov/21482744/
  9. Stevens LA, Schmid CH, Greene T, et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int. 2009;75(6):652-660. https://pubmed.ncbi.nlm.nih.gov/19119287/
  10. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352(20):2049-2060. https://pubmed.ncbi.nlm.nih.gov/15901858/
  11. Rangaswami J, Bhatt DL, Grams ME, et al. Cardiorenal protection with the newer diabetic therapies. Circulation. 2023;148(13):1033-1061. https://www.ahajournals.org/doi/10.1161/CIR.0000000000001123
  12. Helal I, Fick-Brosnahan GM, Reed-Gitomer B, Schrier RW. Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat Rev Nephrol. 2012;8(5):293-300. https://pubmed.ncbi.nlm.nih.gov/22349487/
  13. American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes, 2024: Chronic Kidney Disease and Risk Management. Diabetes Care. 2024;47(Suppl 1):S219-S230. https://diabetesjournals.org/care/article/47/Supplement_1/S219/153946/11-Chronic-Kidney-Disease-and-Risk-Management
  14. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-2116. https://pubmed.ncbi.nlm.nih.gov/26551272/
  15. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy (CREDENCE). N Engl J Med. 2019;380(24):2295-2306. https://pubmed.ncbi.nlm.nih.gov/30990260/
  16. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease (DAPA-CKD). N Engl J Med. 2020;383(15):1436-1446. https://pubmed.ncbi.nlm.nih.gov/32970396/
  17. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ. 2000;321(7258):405-412. https://pubmed.ncbi.nlm.nih.gov/10938048/
  18. Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med. 2024;391(2):109-121. https://pubmed.ncbi.nlm.nih.gov/38785209/
  19. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease (MDRD). N Engl J Med. 1994;330(13):877-884. https://pubmed.ncbi.nlm.nih.gov/8114857/
  20. Hsu CY, McCulloch CE, Fan D, et al. Community-based incidence of acute renal failure. Kidney Int. 2007;72(2):208-212. https://pubmed.ncbi.nlm.nih.gov/17507907/
  21. Agarwal R. Nephrotoxicity of commonly used drugs. Kidney Int. 2019;95(2):260-262. https://pubmed.ncbi.nlm.nih.gov/30665573/
  22. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
  23. National Institute for Health and Care Excellence. Chronic kidney disease in adults: assessment and management (CG182). 2014; updated 2021. https://pubmed.ncbi.nlm.nih.gov/25340248/